{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:20:48Z","timestamp":1792167648166,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN268201000043C"],"award-info":[{"award-number":["HHSN268201000043C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL095070"],"award-info":[{"award-number":["HL095070"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL113451"],"award-info":[{"award-number":["HL113451"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL114772"],"award-info":[{"award-number":["HL114772"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 GM-008433"],"award-info":[{"award-number":["T32 GM-008433"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.atherosclerosis.2022.01.002","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T01:58:48Z","timestamp":1642730328000},"page":"20-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Hypoxia inducible factor 1\u03b1 inhibitor PX-478 reduces atherosclerosis in mice"],"prefix":"10.1016","volume":"344","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2981-9330","authenticated-orcid":false,"given":"Nicolas","family":"Villa-Roel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2848-4695","authenticated-orcid":false,"given":"Kitae","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Fernandez Esmerats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Won","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3440-3628","authenticated-orcid":false,"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1833-372X","authenticated-orcid":false,"given":"Hanjoong","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.01.002_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.01.002_bib2","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.2538","article-title":"Atherosclerosis: current pathogenesis and therapeutic options","volume":"17","author":"Weber","year":"2011","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2022.01.002_bib3","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American heart association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.01.002_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.biopha.2018.05.024","article-title":"Role of PCSK9 in lipid metabolism and atherosclerosis","volume":"104","author":"Lin","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.01.002_bib5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/10408363.2014.992063","article-title":"Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases","volume":"52","author":"Trpkovic","year":"2015","journal-title":"Crit. Rev. Clin. Lab Sci."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.01.002_bib6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamacardio.2016.1884","article-title":"Association of lipid fractions with risks for coronary artery disease and diabetes","volume":"1","author":"White","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"9438","key":"10.1016\/j.atherosclerosis.2022.01.002_bib7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.01.002_bib8","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1161\/CIRCRESAHA.115.306884","article-title":"Vascular complications of diabetes","volume":"118","author":"Beckman","year":"2016","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2022.01.002_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11883-016-0632-z","article-title":"The different facets of dyslipidemia and hypertension in atherosclerosis","volume":"18","author":"Hurtubise","year":"2016","journal-title":"Curr. Atherosclerosis Rep."},{"issue":"34","key":"10.1016\/j.atherosclerosis.2022.01.002_bib10","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.2174\/092986732134141015161539","article-title":"Smoking and atherosclerosis: mechanisms of disease and new therapeutic approaches","volume":"21","author":"Siasos","year":"2014","journal-title":"Curr. Med. Chem."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.01.002_bib11","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/jclinpath-2012-200828","article-title":"The role of hypoxia-inducible factor 1 in atherosclerosis","volume":"65","author":"Gao","year":"2012","journal-title":"J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.01.002_bib12","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.atherosclerosis.2007.05.026","article-title":"HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages","volume":"195","author":"Vink","year":"2007","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2022.01.002_bib13","doi-asserted-by":"crossref","first-page":"884","DOI":"10.5551\/jat.RV17009","article-title":"The roles of hypoxia signaling in the pathogenesis of cardiovascular diseases","volume":"24","author":"Abe","year":"2017","journal-title":"J. Atherosclerosis Thromb."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.01.002_bib14","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0003319716662423","article-title":"Hypoxia in atherogenesis","volume":"68","author":"Ferns","year":"2017","journal-title":"Angiology"},{"issue":"13","key":"10.1016\/j.atherosclerosis.2022.01.002_bib15","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jacc.2007.12.025","article-title":"Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis","volume":"51","author":"Sluimer","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.01.002_bib16","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1161\/ATVBAHA.117.309249","article-title":"Mechanical activation of hypoxia-inducible factor 1\u03b1 drives endothelial dysfunction at atheroprone sites","volume":"37","author":"Feng","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.01.002_bib17","first-page":"242","article-title":"Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction","volume":"8","author":"Ten","year":"2002","journal-title":"Curr. Opin. Crit. Care"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.01.002_bib18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/jcb.25074","article-title":"Regulation of hypoxia-inducible factor-1a by reactive oxygen species: new developments in an old debate","volume":"116","author":"Movafagh","year":"2015","journal-title":"J. Cell. Biochem."},{"issue":"6733","key":"10.1016\/j.atherosclerosis.2022.01.002_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2022.01.002_bib20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/35017054","article-title":"Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein","volume":"2","author":"Ohh","year":"2000","journal-title":"Nat. Cell Biol."},{"issue":"36","key":"10.1016\/j.atherosclerosis.2022.01.002_bib21","doi-asserted-by":"crossref","first-page":"22642","DOI":"10.1074\/jbc.272.36.22642","article-title":"Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes","volume":"272","author":"Salceda","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.atherosclerosis.2022.01.002_bib22","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1093\/emboj\/19.16.4298","article-title":"Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein","volume":"19","author":"Tanimoto","year":"2000","journal-title":"EMBO J."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2022.01.002_bib23","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1073\/pnas.080072497","article-title":"Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations","volume":"97","author":"Sutter","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2022.01.002_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/978-1-4757-3401-0_24","article-title":"The pVHL-hIF-1 system. A key mediator of oxygen homeostasis","volume":"502","author":"Maxwell","year":"2001","journal-title":"Adv. Exp. Med. Biol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.01.002_bib25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"Pt 3","key":"10.1016\/j.atherosclerosis.2022.01.002_bib26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1042\/BJ20040620","article-title":"Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases","volume":"381","author":"Marxsen","year":"2004","journal-title":"Biochem. J."},{"issue":"5516","key":"10.1016\/j.atherosclerosis.2022.01.002_bib27","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"issue":"5516","key":"10.1016\/j.atherosclerosis.2022.01.002_bib28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.01.002_bib29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ncb2424","article-title":"The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity","volume":"14","author":"Foxler","year":"2012","journal-title":"Nat. Cell Biol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.01.002_bib30","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1172\/JCI84431","article-title":"HIF1alpha and metabolic reprogramming in inflammation","volume":"126","author":"Corcoran","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"38","key":"10.1016\/j.atherosclerosis.2022.01.002_bib31","doi-asserted-by":"crossref","first-page":"23757","DOI":"10.1016\/S0021-9258(17)31580-6","article-title":"Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1","volume":"269","author":"Semenza","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"6692","key":"10.1016\/j.atherosclerosis.2022.01.002_bib32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/28867","article-title":"Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis","volume":"394","author":"Carmeliet","year":"1998","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.01.002_bib33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/cdd.2008.12","article-title":"Biology of HIF-1alpha","volume":"15","author":"Weidemann","year":"2008","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.01.002_bib34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1535-7163.MCT-07-0463","article-title":"Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha","volume":"7","author":"Koh","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.01.002_bib35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/1535-7163.233.3.3","article-title":"Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha","volume":"3","author":"Welsh","year":"2004","journal-title":"Mol. Cancer Therapeut."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.01.002_bib36","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/ijc.23807","article-title":"PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells","volume":"123","author":"Palayoor","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2022.01.002_bib37","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/JTO.0b013e3181dc211f","article-title":"Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice","volume":"5","author":"Jacoby","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.atherosclerosis.2022.01.002_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.3076","article-title":"Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1\u03b1","volume":"28","author":"Tibes","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.01.002_bib39","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1128\/MCB.00951-12","article-title":"Selective inhibition of hypoxia-inducible factor 1alpha ameliorates adipose tissue dysfunction","volume":"33","author":"Sun","year":"2013","journal-title":"Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.01.002_bib40","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1161\/HYPERTENSIONAHA.115.05886","article-title":"Endothelial hypoxia-inducible factor-1\u03b1 promotes atherosclerosis and monocyte recruitment by upregulating MicroRNA-19a","volume":"66","author":"Akhtar","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.atherosclerosis.2022.01.002_bib41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev-fluid-010313-141309","article-title":"Fluid mechanics, arterial disease, and gene expression","volume":"46","author":"Tarbell","year":"2014","journal-title":"Annu. Rev. Fluid Mech."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.01.002_bib42","doi-asserted-by":"crossref","first-page":"140039","DOI":"10.1038\/sdata.2014.39","article-title":"Flow-dependent regulation of genome-wide mRNA and microRNA expression in endothelial cells in vivo","volume":"1","author":"Kumar","year":"2014","journal-title":"Sci. Data"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.01.002_bib43","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/ATVBAHA.118.312233","article-title":"Disturbed flow increases UBE2C (ubiquitin E2 Ligase C) via Loss of miR-483-3p, inducing aortic valve calcification by the pVHL (von Hippel-Lindau protein) and HIF-1alpha (Hypoxia-Inducible factor-1alpha) pathway in endothelial cells","volume":"39","author":"Fernandez Esmerats","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2022.01.002_bib44","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/labinvest.2017.47","article-title":"Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation","volume":"97","author":"Kumar","year":"2017","journal-title":"Lab. Invest."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.01.002_bib45","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1158\/1535-7163.MCT-08-0510","article-title":"A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth","volume":"7","author":"Greenberger","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.01.002_bib46","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1021\/acschembio.1c00387","article-title":"Conditional antisense oligonucleotides triggered by miRNA","volume":"16","author":"Zhang","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.01.002_bib47","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/978-1-4939-3578-9_19","article-title":"It's DE-licious: a recipe for differential expression analyses of RNA-seq experiments using quasi-Likelihood methods in edgeR","volume":"1418","author":"Lun","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.01.002_bib48","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1038\/ncomms4000","article-title":"The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis","volume":"4","author":"Son","year":"2013","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.01.002_bib49","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/CIRCRESAHA.115.304008","article-title":"AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia","volume":"115","author":"Somanathan","year":"2014","journal-title":"Circ. Res."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2022.01.002_bib50","doi-asserted-by":"crossref","first-page":"e0162228","DOI":"10.1371\/journal.pone.0162228","article-title":"Small molecule-induced complement factor D (adipsin) promotes lipid accumulation and adipocyte differentiation","volume":"11","author":"Song","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2022.01.002_bib51","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1074\/jbc.M511588200","article-title":"ELOVL3 is an important component for early onset of lipid recruitment in brown adipose tissue","volume":"281","author":"Westerberg","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.01.002_bib52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2005.12.022","article-title":"Protein sensors for membrane sterols","volume":"124","author":"Goldstein","year":"2006","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.01.002_bib53","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12944-016-0402-5","article-title":"Mouse models of atherosclerosis: a historical perspective and recent advances","volume":"16","author":"Lee","year":"2017","journal-title":"Lipids Health Dis."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.01.002_bib54","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/ATVBAHA.108.172270","article-title":"Site-specific effects of PECAM-1 on atherosclerosis in LDL receptor-deficient mice","volume":"28","author":"Goel","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.01.002_bib55","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1161\/ATVBAHA.108.164707","article-title":"Endothelial cell PECAM-1 promotes atherosclerotic lesions in areas of disturbed flow in ApoE-deficient mice","volume":"28","author":"Harry","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.01.002_bib56","doi-asserted-by":"crossref","first-page":"17593","DOI":"10.1038\/s41598-020-74617-5","article-title":"HFD-induced hepatic lipid accumulation and inflammation are decreased in Factor D deficient mouse","volume":"10","author":"Tsuru","year":"2020","journal-title":"Sci. Rep."},{"issue":"23","key":"10.1016\/j.atherosclerosis.2022.01.002_bib57","doi-asserted-by":"crossref","first-page":"e013716","DOI":"10.1161\/JAHA.119.013716","article-title":"Identification of adipsin as a novel prognostic biomarker in patients with coronary artery disease","volume":"8","author":"Ohtsuki","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2022.01.002_bib58","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.2174\/0929867326666191001130342","article-title":"Discovery and development of the oral complement factor D inhibitor danicopan (ACH-4471)","volume":"27","author":"Wiles","year":"2020","journal-title":"Curr. Med. Chem."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022000168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022000168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:47:58Z","timestamp":1758156478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915022000168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":58,"alternative-id":["S0021915022000168"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.01.002","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypoxia inducible factor 1\u03b1 inhibitor PX-478 reduces atherosclerosis in mice","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}